Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181

Benzinga · 1d ago
Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $158 to $181.